Corcept Therapeutics (CORT) EBT (2010 - 2026)
Corcept Therapeutics (CORT) posted EBT of $45.9 million for Q2 2026, up 202.72% sequentially from -$44.7 million in Q1 2026, and up 44.93% YoY from $31.7 million in Q2 2025.
Corcept Therapeutics (CORT) EBT (2010 - 2026) Analysis & Trends
Corcept Therapeutics has reported EBT for 17 years, with the latest figure at $45.9 million in Q2 2026.
- Quarterly EBT rose 44.93% year-over-year to $45.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $26.4 million (down 79.11% YoY) and the FY2025 annual result came in at $66.5 million, down 58.84% from the prior year.
- EBT improved to $45.9 million in Q2 2026 per CORT's latest filing, from -$44.7 million in the prior quarter.
- Over five years, EBT peaked at $52.9 million in Q3 2024 and troughed at -$44.7 million in Q1 2026.
- A 5-year average of $26.1 million and a median of $32.0 million in 2022 frame the typical range for EBT.
- The sharpest annual moves came in 2024 and 2026: EBT soared 89.83% in 2024, then sank 564.91% in 2026.
- Over 5 years, EBT stood at $24.3 million in 2022, then surged by 51.63% to $36.8 million in 2023, then retreated by 13.17% to $32.0 million in 2024, then tumbled by 68.99% to $9.9 million in 2025, then jumped by 363.48% to $45.9 million in 2026.
- According to Business Quant data, EBT over the past three periods registered $45.9 million, -$44.7 million, and $9.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn | 45.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.93 Mn |
| Mar 31, 2026 | -44.72 Mn |
| Dec 31, 2025 | 9.91 Mn |
| Sep 30, 2025 | 15.24 Mn |
| Jun 30, 2025 | 31.69 Mn |
| Mar 31, 2025 | 9.62 Mn |
| Dec 31, 2024 | 31.96 Mn |
| Sep 30, 2024 | 52.94 Mn |
| Jun 30, 2024 | 41.60 Mn |
| Mar 31, 2024 | 34.99 Mn |
| Dec 31, 2023 | 36.81 Mn |
| Sep 30, 2023 | 36.39 Mn |
| Jun 30, 2023 | 32.93 Mn |
| Mar 31, 2023 | 18.43 Mn |
| Dec 31, 2022 | 24.28 Mn |
| Sep 30, 2022 | 33.00 Mn |
| Jun 30, 2022 | 32.06 Mn |
| Mar 31, 2022 | 26.85 Mn |
| Dec 31, 2021 | 36.74 Mn |
| Sep 30, 2021 | 36.30 Mn |